betamethasone/calcipotriol (BFH 772) / Novartis - LARVOL DELTA

Topical Betamethasone/Calcipotriol creme as an Effective Add‑On Therapy for Residual Psoriasis Plaques: Two Clinical Cases (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis

Paradoxical Immune Reactions under IL-17 Blockade: Insights from a Clinical Case Series (EADV-Sp 2026) - "Topical treatment with mometasone furoate ointment and keratolytic agents was initiated...Case 2: A 50-year-old female patient with a history of psoriatic arthritis (PsA) since 2021 and PV since 2022 was switched to ixekizumab in December 2022 after methotrexate (MTX) and apremilast proved ineffective...Topical treatment with calcipotriol and betamethasone dipropionate foam was prescribed, leading to a favorable clinical response...However, worsening of PV prompted a switch to adalimumab in August 2023, followed by a further switch to risankizumab in October 2024 due to fluctuating disease activity. Case 4: A 56-year-old woman with palmoplantar PV and autoimmune thyroiditis was started on ixekizumab in November 2025 after failure of MTX and topical therapies (betamethasone+calcipotriol and tazarotene)...Ixekizumab was discontinued, and treatment with topical steroids and systemic colchicine was initiated, resulting in marked improvement within two months...Conclusions..."

Clinical • Endocrine Disorders • Immunology • Inflammatory Arthritis • Plaque Psoriasis • Psoriasis • Psoriatic Arthritis • Pustular Psoriasis • Seronegative Spondyloarthropathies

Application of Trichoscopy and Novel Non-Invasive Imaging Techniques in the Diagnosis and Management of Patients with Scalp Psoriasis. (PubMed, Psoriasis (Auckl)) - "Topical therapies (glucocorticosteroids, a betamethasone-calcipotriol combination or calcineurin inhibitors) remain the first-line therapy for mild to moderate cases. Patients with severe scalp psoriasis and those who do not respond to topical treatment are candidates for systemic therapy, including targeted therapy (interleukin-17 inhibitors, interleukin-23 inhibitors, tumor necrosis alpha inhibitors) or classic treatment (methotrexate, cyclosporine) Recent studies have demonstrated promising outcomes with novel treatments including Janus kinase (JAK) inhibitors and other new small molecules. This review provides updated information focused on diagnostic methods and targeted treatment of scalp psoriasis with relevance to clinical management of patients."

Journal • Review • Dermatology • Dermatopathology • Immunology • Oncology • Psoriasis • IL17A

Betamethasone-Calcipotriol Foam: A Promising Treatment for Erythema Annulare Centrifugum With LC-OCT Monitoring. (PubMed, Dermatol Pract Concept) - No abstract available

Journal • Dermatology

Biological therapy enhances microvascular reactivity in psoriasis via improved endothelial function: a pilot study (EADV 2025) - "Materials & This cross-sectional pilot study involved 41 psoriasis patients who received topical therapy (PV-local; betamethasone or betamethasone-calcipotriol combination), 12 psoriasis patients who received anti- IL17 and anti-IL23 biological therapy (PV-biological), and 30 age- and sex-matched healthy controls. Laser Doppler flowmetry was used to measure microvascular reactivity in response to vascular occlusion (PORH) and iontophoresis of acetylcholine (AChID), as indicators of endothelium-dependent vasodilation, and in response to iontophoresis of sodium nitroprusside (SNPID), as an indicator of endothelium-independent vasodilation... Psoriasis patients on topical therapy alone tended to have attenuated endothelium-dependent vasodilation and increased serum fibrinogen levels compared with those treated with biological therapy. Larger, well-designed studies are needed to confirm the long-term vascular benefits of biological therapies in psoriasis."

Clinical • Atherosclerosis • Cardiovascular • Dermatology • Immunology • Inflammation • Psoriasis • CRP • IL17A

Drug repositioning for rosacea disease: Biological TARGET identification, molecular docking, pharmacophore mapping, and molecular dynamics analysis. (PubMed, Comput Biol Med) - "Furthermore, considering the drugs currently used for rosacea management, we demonstrated stable interactions between isotretinoin and BFH772 with SKAP2, and permethrin and PAC-14028 with S100A7A. Similarly, considering drugs targeting SKAP2 and S100A7A interactome proteins, we found that pitavastatin and dasatinib exert stable interactions with SKAP2, and lovastatin and tirbanibulin with S100A7A...In conclusion, our study provides evidence for the possible contribution of SKAP2 and S100A7A to rosacea pathology. Furthermore, it provides significant information on the molecular interactions between drugs and these proteins, highlighting the importance of considering structural features and binding interactions in the design of targeted therapies for skin disorders such as rosacea."

Journal • Dermatology • Dermatopathology • Rosacea • SKAP2

Calcipotriol/Betamethasone Dipropionate for the Treatment of Psoriasis: Mechanism of Action and Evidence of Efficacy and Safety versus Topical Corticosteroids. (PubMed, J Clin Med) - "The combination therapy rapid onset of action, coupled with a simplified dosing regimen, has been identified as crucial for improving long-term adherence and patient outcomes. In conclusion, Cal/BDP is confirmed as a versatile, effective, and convenient option for the patient in psoriasis management."

Clinical • Journal • Review • Dermatology • Immunology • Psoriasis

Pustular psoriasis following COVID-19: successful bimekizumab treatment. (EADV-Sp 2024) - "He was on risankizumab and had previously received topical betamethasone/calcipotriol, UVB phototherapy, acitretin and apremilast. Despite the need for further evidence, the significant and rapid improvement of these patients suggests that bimekizumab may have an important role in the management of pustular psoriasis."

Atrial Fibrillation • Cardiovascular • Chronic Obstructive Pulmonary Disease • Coronary Artery Disease • Cough • Dermatology • Diabetes • Heart Failure • Hypertension • Immunology • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Psoriasis • Pulmonary Disease • Pustular Psoriasis • Respiratory Diseases

A case of IgA pemphigus in a patient with a history of psoriasis (EADV 2023) - "A year ago, he was diagnosed with psoriasis at another hospital and was undergoing oral cyclosporine, topical betamethasone/calcipotriol and tacrolimus treatment. Dermatologists managing patients with psoriasis should be aware of this epidemiological feature that bullous diseases can be associated with psoriasis, and prospective studies are required to further delineate their relation."

Clinical • Dermatology • Dermatopathology • Immunology • Inflammation • Psoriasis

Cost-Effectiveness Analysis of Halobetasol and Tazarotene (DUOBRIITM) Compared to Standard of Care for Adult Patients with Moderate-to-Severe Plaque Psoriasis in Québec (ISPOR 2023) - "The SoC (betamethasone/calcipotriol [BD/VDA] followed by [>] systemic therapy [ST]; [BD/VDA>ST]) was compared to HP/TAZ>ST. Considering the chronic nature of plaque psoriasis, adding HP/TAZ to SoC would lead to considerable long-term savings in Quebec while improving population health."

Clinical • Cost effectiveness • HEOR • Dermatology • Immunology • Psoriasis

Fractional CO2 Laser versus Fractional CO2 Laser Plus Betamethasone/Calcipotriol Ointment in the Treatment of Nail Psoriasis. (PubMed, Dermatol Surg) - "Fractional CO2 laser can be an effective and promising new treatment for nail psoriasis."

Journal • Dermatology • Immunology • Psoriasis

Prospective Observational Evaluation of Fixed Combination Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in the Management of Psoriasis with Scalp Involvement in Everyday Clinical Practice (the CAPITIS Study). (PubMed, Dermatology) - "This study demonstrated the effectiveness, rapid onset of action, good tolerability, and good safety profile of the Cal/BD aerosol foam in patients with scalp psoriasis treated in a real-world setting."

Clinical • Journal • Observational data • Dermatology • Immunology • Pruritus • Psoriasis

Efficacy of Calcipotriol/Betamethasone Dipropionate Fixed-Combination Aerosol Foam in the Treatment of Localized Scalp Psoriasis: A Real-Life Case Series from Switzerland. (PubMed, Dermatol Ther (Heidelb)) - "Our case series confirms that Cal/BD foam is a rapid, effective, and convenient treatment for localized scalp psoriasis in a nonselected real-world patient cohort refractory to TCS or other local treatments. Clear application instructions are crucial for treatment success and cosmetic acceptance, however."

Journal • Dermatology • Immunology • Psoriasis

Sub-population analysis of patients with plaque psoriasis treated with calcipotriol/betamethasone aerosol foam; effectiveness and patient satisfaction, according to baseline disease severity and prior psoriasis treatment experience, in a Greek population. (PubMed, Dermatol Ther) - "Reduction from baseline in psoriasis symptoms was observed in all patient groups. The greatest reductions were observed in treatment-naïve patients with severe disease. Clinically relevant benefits were observed with Cal/BD aerosol foam in psoriasis patients, regardless of prior treatment-experience and disease severity at baseline."

Journal • Dermatology • Immunology • Psoriasis

Pulse-Dye Laser Followed by Betamethasone-Calcipotriol and Fractional Ablative CO2-Laser-Assisted Delivery for Nail Psoriasis. (PubMed, Dermatol Surg) - "Combined PDL and fractional ablative CO2-LADD of betamethasone-calcipotriol gel should be considered for the treatment of nail psoriasis."

Journal • Dermatology • Immunology • Pain • Psoriasis

Paradoxical psoriasis caused by tumour necrosis factor-a inhibitor therapy: a report of seven cases from a single centre (BAD 2017) - "...We report seven patients (four female, three male, aged 34–43 years) who developed paradoxical psoriasis following treatment with TNFi therapy: adalimumab (n = 3), infliximab (n = 2) and certolizumab (n = 2)...One patient, who developed paradoxical plaque psoriasis secondary to infliximab, was able to remain on this drug and was managed topically with betamethasone/calcipotriol with good control. However, topical therapies (including 60% clobetasol with 40% propylene glycol for PPP) had limited efficacy for the remaining six patients and subsequently the causative TNFi was stopped...Two patients were commenced on ustekinumab and improvement was observed after 10–12 weeks...To our knowledge little is known about the mechanism underlying its development; however, it has been postulated that upregulation of interferon secondary to TNF-a blockade could be contributory. Therefore, switching to a biological therapy with an alternate mechanism of action may be beneficial."

Clinical • Ankylosing Spondylitis • Biosimilar • Immunology • Inflammatory Bowel Disease • Ophthalmology • Psoriasis • Sarcoidosis

Efficacy of Calcipotriol-Betamethasone Ointment in Patients with Mild to Moderate Plaque Psoriasis: Subgroup Analyses. (PubMed, Dermatology) - "Increased BMI and obesity present risk factors for reduced treatment effectiveness. Importantly, the efficacy of calcipotriol-betamethasone ointment was consistent in all subgroups."

Clinical • Journal

Patient and Physician Satisfaction with Calcipotriol and Betamethasone Dipropionate Aerosol Foam in the Treatment of Plaque Psoriasis on the Body. (PubMed, Actas Dermosifiliogr) - "Both patients and physicians expressed high satisfaction with the use of Cal/BD aerosol foam for the treatment of plaque psoriasis on the body."

Clinical • Journal

Sensitivity of Different In Vitro Performance Tests and Their In Vivo Relevance for Calcipotriol/Betamethasone Ointment. (PubMed, Pharm Res) - "The results of in vitro experiments rank orderly correlated with the results of clinical study. In vitro methods are more sensitive and highly discriminatory when compared to in vivo performance."

Journal • Preclinical

Differential effects of phototherapy, adalimumab and betamethasone/calcipotriol on effector and regulatory T cells in psoriasis. (PubMed, Br J Dermatol) - "The differential effects reported here for the above-mentioned treatment modalities could be exploited to optimize or design therapeutic strategies to better overcome the inflammatory drivers and restore the Th17/Treg balance in psoriasis."

Journal • Preclinical